Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 42, 2016, Pages E6467-E6475

  Albanese, Manuel ^a,b   Tagawa, Takanobu ^a,b   Bouvet, Mickaël ^a,b   Maliqi, Liridona ^a,b   Lutter, Dominik ^a   Hoser, Jonathan ^a   Hastreiter, Maximilian ^a   Hayes, Mitch ^c   Sugden, Bill ^c   Martin, Larissa ^a,b   Moosmann, Andreas ^a,b   Hammerschmidt, Wolfgang ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b German Center for Infection Research   (Germany)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Adaptive immunity; CD8 T cells; Herpesvirus; Immune evasion; MicroRNA

Indexed keywords

CARRIER PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 1; GAMMA INTERFERON; INTERLEUKIN 12; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TAP2 PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; CYTOKINE; CYTOKINE RECEPTOR; EPITOPE; HLA ANTIGEN CLASS 1; MICRORNA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOSURVEILLANCE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; B LYMPHOCYTE; CELL LINE; CELL SURVIVAL; CYTOTOXICITY; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; VIROLOGY;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SURVIVAL; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; IMMUNOLOGIC SURVEILLANCE; MICRORNAS; RECEPTORS, CYTOKINE; RNA, VIRAL;

EID: 84991666745     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1605884113     Document Type: Article

References (70)

1. van Baarle D, et al. (2001) Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 98(1):146-155.
2. Smets F, et al. (2002) Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73(10):1603-1610.
3. Landgren O, et al. (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113(20):4992-5001.
4. Heslop HE, et al. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5):925-935.
5. Moosmann A, et al. (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115(14):2960-2970.
6. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 25:587-617.
7. Bihl F, et al. (2006) Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 176(7):4094-4101.
8. Kalla M, Göbel C, Hammerschmidt W (2012) The lytic phase of Epstein-Barr virus requires a viral genome with 5-methylcytosine residues in CpG sites. JVirol86(1):447-458.
9. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350(13):1328-1337.
10. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB (1992) Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66(1):122-131.
11. Longnecker RM, Kieff E, Cohen JI (2013) in Fields Virology, eds Knipe DM, et al. (Wolters Kluver, Philadelphia), Vol 2, pp 1898-1959.
12. Joseph AM, Babcock GJ, Thorley-Lawson DA (2000) Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74(21):9964-9971.
13. Hammerschmidt W (2015) The epigenetic life cycle of Epstein-Barr virus. Curr Top Microbiol Immunol 390(Pt 1):103-117.
14. Hislop AD, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204(8):1863-1873.
15. Horst D, et al. (2009) Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol 182(4):2313-2324.
16. Zuo J, et al. (2009) The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 5(1):e1000255.
17. Zuo J, et al. (2011) The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. J Virol 85(4):1604-1614.
18. Rowe M, et al. (2007) Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA 104(9):3366-3371.
19. Zuo J, et al. (2008) The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. JVirol82(5):2385-2393.
20. Quinn LL, et al. (2015) The missing link in Epstein-Barr Virus immune evasion: The BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II. J Virol 90(1):356-367.
21. Croft NP, et al. (2009) Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 5(6):e1000490.
22. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R (2012) The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog 8(5):e1002704.
23. Cassell DJ, Schwartz RH (1994) A quantitative analysis of antigen-presenting cell function: Activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation. J Exp Med 180(5):1829-1840.
24. Wiesner M, et al. (2008) Conditional immortalization of human B cells by CD40 ligation. PLoS One 3(1):e1464.
25. Rowe M, et al. (1991) Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173(1):147-158.
26. Lautscham G, et al. (2003) Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. J Virol 77(4):2757-2761.
27. Hill AB, et al. (1995) Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 181(6):2221-2228.
28. Pfeffer S, et al. (2004) Identification of virus-encoded microRNAs. Science 304(5671):734-736.
29. Pfeffer S, et al. (2005) Identification of microRNAs of the herpesvirus family. Nat Methods 2(4):269-276.
30. Cai X, et al. (2006) Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2(3):e23.
31. Kincaid RP, Sullivan CS (2012) Virus-encoded microRNAs: An overview and a look to the future. PLoS Pathog 8(12):e1003018.
32. Haneklaus M, et al. (2012) Cutting edge: MiR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol 189(8):3795-3799.
33. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O (2009) Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5(4):376-385.
34. Xia T, et al. (2008) EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 68(5):1436-1442.
35. Tagawa T, et al. (2016) Epstein-Barr viral miRNAs inhibit antiviral CD4+ T-cell responses targeting IL-12 and peptide processing. J Exp Med, 10.1084/jem.20160248.
36. Seto E, et al. (2010) Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog 6(8):e1001063.
37. Feederle R, et al. (2011) A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog 7(2):e1001294.
38. Feederle R, et al. (2011) The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. J Virol 85(19):9801-9810.
39. Lautscham G, et al. (2001) Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J Exp Med 194(8):1053-1068.
40. Dölken L, et al. (2010) Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe 7(4):324-334.
41. Garcia DM, et al. (2011) Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 18(10):1139-1146.
42. Del Val M, Lázaro S, Ramos M, Antón LC (2013) Are membrane proteins favored over cytosolic proteins in TAP-independent processing pathways? Mol Immunol 55(2):117-119.
43. Lo AK, et al. (2007) Modulation of LMP1 protein expression by EBV-encoded micro- RNAs. Proc Natl Acad Sci USA 104(41):16164-16169.
44. Riley KJ, et al. (2012) EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J 31(9):2207-2221.
45. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R (1992) Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 143(1):127-142.
46. Long HM, et al. (2005) CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. JVirol79(8):4896-4907.
47. Jochum S, Ruiss R, Moosmann A, Hammerschmidt W, Zeidler R (2012) RNAs in Epstein-Barr virions control early steps of infection. Proc Natl Acad Sci USA 109(21):E1396-E1404.
48. Qiu J, et al. (2011) A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog 7(8):e1002193.
49. Kim DN, et al. (2007) Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol 81(2):1033-1036.
50. Gottschalk S, et al. (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97(4):835-843.
51. Khanna R, et al. (1997) Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: Evidence for immune pressure-independent genetic drift. J Virol 71(11):8340-8346.
52. Midgley RS, Bell AI, McGeoch DJ, Rickinson AB (2003) Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes. J Virol 77(21):11517-11530.
53. Midgley RS, et al. (2003) HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: Incidence and immunogenicity of variant epitope sequences. J Virol 77(21):11507-11516.
54. Ressing ME, Luteijn RD, Horst D, Wiertz EJ (2013) Viral interference with antigen presentation: Trapping TAP. Mol Immunol 55(2):139-142.
55. Verweij MC, et al. (2015) Viral inhibition of the transporter associated with antigen processing (TAP): A striking example of functional convergent evolution. PLoS Pathog 11(4):e1004743.
56. Weinzierl AO, et al. (2008) Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol 38(6):1503-1510.
57. Sutton J, et al. (1993) A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol 23(2):447-453.
58. Falk K, et al. (1995) Peptide motifs of HLA-B58, B60, B61, and B62 molecules. Immunogenetics 41(2-3):165-168.
59. Kobayashi M, et al. (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170(3):827-845.
60. Manetti R, et al. (1994) Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 179(4):1273-1283.
61. Valiante NM, Rengaraju M, Trinchieri G (1992) Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 145(1):187-198.
62. Kaech SM, Cui W (2012) Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 12(11):749-761.
63. Starbeck-Miller GR, Xue HH, Harty JT (2014) IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. J Exp Med 211(1):105-120.
64. Elloso MM, Scott P (2001) Differential requirement of CD28 for IL-12 receptor expression and function in CD4(+) and CD8(+) T cells. Eur J Immunol 31(2):384-395.
65. Steinbrück L, et al. (2015) K1 and K15 of Kaposi's sarcoma-associated herpesvirus are partial functional homologues of latent membrane protein 2A of Epstein-Barr virus. J Virol 89(14):7248-7261.
66. Adhikary D, et al. (2007) Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One 2(7):e583.
67. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A (2015) Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T cells. PLoS Pathog 11(6):e1004906.
68. Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A (2010) Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J Virol 84(7):3612-3623.
69. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 95(14):8245-8250.
70. Haraguchi T, Ozaki Y, Iba H (2009) Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res 37(6):e43.